We at Cybion are proud to announce today that we have extended our distribution agreement for the Transverse Tibia Transport (TTT)-System.
The new exclusive distribution territories are the USA and the Middle East. This step is another milestone for Cybion as the US market has the highest number of diabetes patients. There are approximately 130,000 lower limb amputations caused by diabetes every year.
The TTT-System for treating severe diabetic foot ulcers (DFU) is designed to prevent amputations of the lower limb to allow patients to return to their daily lives.
We are pleased to be able to offer a life-changing treatment for these patients.